Vaccines Li-Anne Rowswell Mufson Vaccines Li-Anne Rowswell Mufson

Bird Flu Vaccine Funding Cuts: Critical Error

Bird Flue Vaccine Funding

By Michael Bronfman for Metis, June 30, 2025

H5N1 Bird flu vaccines

We at Metis are very concerned about a dangerous misstep by the Department of Health and Human Services (HHS) when it recently terminated a $700 million contract with a major pharmaceutical company for their H5N1 mRNA vaccine. Michael Bronfman writes why this is a disturbing trend in the following post. His article contends that bird flu poses a significant, non-theoretical threat with a high mortality rate and increasing human spillover and that current vaccines are outdated. Bronfman champions mRNA technology for its speed and adaptability in vaccine development, directly countering the current administration's skepticism and warning that the funding cut will lead to preparedness gaps, economic fallout, and a loss of public trust due to misinformation. He also tells us why we urgently need to restore funding, enhance surveillance, expand stockpiles, combat misinformation, and implement "One Health" strategies to prevent a potentially catastrophic H5N1 pandemic.

At the end of May 2025, the Department of Health and Human Services (HHS) announced the termination of a roughly $700 million contract with Moderna, aimed at developing an mRNA vaccine for H5N1 bird flu. See: statnews.com+9usnews.com+9english.almayadeen.net+9economictimes.indiatimes.com+12vpm.org+12wprl.org+12.

This decision—from Health Secretary RFK Jr., a noted vaccine skeptic—marks a stark departure from past pandemic preparedness strategies. But why is this move so far-reaching—and so dangerous?

1. Bird Flu Isn't a Theoretical Threat

If H5N1 evolves into a transmissible strain, its impact could eclipse that of
COVID-19.

2. Vaccine Research Is Our First Line of Defense

A. Existing Vaccines Are Outdated

Three U.S.-licensed H5N1 vaccines (2007–2020) are available but target older strains and are held for stockpiling—not mass distribution. See: benzinga.com+14asm.org+14hms.harvard.edu+14. As Harvard experts warn, these old vaccines "do not match the current strains" and require urgent updating. See: hms.harvard.edu.

B. mRNA Offers Speed and Flexibility

C. Real-Time Preclinical Success

New vaccines—both traditional recombinant protein-based and mRNA—have demonstrated full protection in animal models, including mice, ferrets, and cattle. See:  pci.upenn.edu+1time.com+1.

Bottom line: mRNA is not theoretical—it's a demonstrated, powerful tool for pandemic preparedness.

3. Why Cutting the Funding Is Risky

A. Science Vs. Skepticism

Secretary Kennedy cited "safety concerns with mRNA vaccines," stating the Moderna H5N1 shots were "under‑tested". See dvm360.com+15pulmonologyadvisor.com+15arstechnica.com+15. Yet, Moderna's clinical data showed strong immune responses and good tolerability. See: time.com+2pulmonologyadvisor.com+2axios.com+2. Public health experts warn that this move prioritizes vaccine skepticism over solid science. See: reuters.com+2washingtonpost.com+2english.almayadeen.net+2

B. Preparedness Gaps

If H5N1 mutates and spreads easily, the U.S. could find itself without a viable, scalable vaccine. Traditional egg-based production is hampered by the virus's impact on poultry, and updating older vaccines could take months. See: washingtonpost.com+1statnews.com+1. The mRNA approach was designed to bridge that gap.

C. Economic and Social Fallout

Historical models, like the 1957 and 1918 flu, show pandemics impose massive economic costs—healthcare strain, GDP shrinkage up to 5 %, and millions of lost work days unmc.edu. A novel H5N1 pandemic could dwarf the 2020 financial collapse. Cutting vaccine funding is effectively playing with fire.

4. The Wildcard: Misinformation and Public Trust

A. Anti-Vaxx Influence

Secretary Kennedy, known for anti-vaccine stances, has:

Scaling back bird flu vaccine research undermines trust at a delicate moment for public health. It adds to the public's overall skepticism.

B. Implications for Public Confidence

When trusted authorities reduce financial investment in vaccines because of vague "integrity concerns," it fuels suspicion. This can cascade into lower uptake of other essential vaccines (influenza, measles, COVID-19 boosters), increasing vulnerability to both seasonal and pandemic respiratory diseases.

5. Why We Must Continue This Research

A. Vaccines = Prevention

Even if H5N1 doesn't become easily transmissible, vaccines play critical roles by:

  1. Protecting high-risk workers (poultry, livestock, lab personnel) with targeted early vaccination. See: asm.org.

  2. Curbing outbreaks in animals, thus reducing animal-to-human spillover through a "One Health" approach.

  3. Building public preparedness, offering science-based assurance before panic sets in.

B. Economic and Global Leadership

Delaying or stopping vaccine development risks:

  • Loss of global influence in response efforts,

  • Supply chain bottlenecks,

  • U.S. reliance on slower foreign-made vaccines.

Weaker preparedness invites more severe outbreaks and greater economic disruption.

C. Technical Innovation

Ongoing mRNA research against H5N1 improves:

  • Safety profiling,

  • Dose optimization,

  • Broad-spectrum vaccine development.

This translates into future readiness—not just for influenza but for unknown zoonotic threats.

6. The Road Ahead: Recommendations

Recommendation Rationale

Restore and protect funding Back Moderna's Phase 3 and other mRNA H5N1 trials—the world can only catch viruses early with swift vaccine deployment.

Scale genomic surveillance Track mutations across birds, mammals, and humans for early warning signs thesun.iethescottishsun.co.uk+5en.wikipedia.org+5asm.org+5thesun.ie+2asm.org+2time.com+2hms.harvard.edu

Expand stockpiles Update existing protein-based vaccines and purchase doses from CSL Seqirus, GSK, and others.

Combat misinformation Reinforce CDC advisory boards and science-based health communication to rebuild public trust.

Implement One Health strategies Combine farm biosecurity, animal vaccination, and human surveillance to halt cross-species spread.

7. Delay and Mixed Signals: Prevention Requires Commitment

These funding cust signal that vaccine readiness is considered optional. In public health, we don't get mulligans. The stakes are too high; scientifically and economically. The world has seen the devastating precedent of COVID-19; letting bird flu simmer unchecked is an even greater gamble.

If we delay now, we may be rewriting the script of the next global catastrophe. Investing in bird flu vaccines—especially with agile mRNA platforms—is not just wise. It's essential.

If you would like to discuss how this affects your organization and what we can do collectively, please get in touch with Metis Consulting Services.

Read More
Vaccines, Advances in Medicine Li-Anne Rowswell Mufson Vaccines, Advances in Medicine Li-Anne Rowswell Mufson

Background of the Breakthroughs of mRNA

By Michael Bronfman, June 23, 2025

Dr. Katalin Kariko, Nobel Prize winning scientist, mRNA vaccine pioneer

This week, The Guard Rail is diving into a topic that has truly revolutionized modern medicine: Messenger RNA, or mRNA. What was once merely a fascinating concept in biology has rapidly become a groundbreaking platform, and its incredible success in the COVID-19 vaccine development is just the beginning. Join us as we explore the captivating scientific journey of mRNA, highlighting the decades of innovation in molecular biology, chemistry, and nanotechnology that led to its triumph. We will also spotlight the key innovators who made it all possible, with a special nod to the remarkable influence of Dr. Katalin Karikó and Dr. Drew Weissman and peek into the exciting future promise of mRNA-based therapeutics.


The Arrival of a New Therapeutic Frontier

Messenger RNA (mRNA) has rapidly transitioned from a biological curiosity to a revolutionary platform in medicine. Its recent triumph—vaccine success against COVID-19—stemmed from decades of incremental yet transformative molecular biology, chemistry, and nanotechnology breakthroughs.


1. From Molecular Discovery to Therapeutic Aspiration

  • 1961 – mRNA Identified

Scientists first recognized mRNA as the key intermediary transmitting genetic information from DNA to ribosomes. This discovery laid the molecular foundation for engineering mRNA for therapeutic use.

  • 1990 – Synthetic mRNA Demonstrated

Jon A. Wolff and colleagues injected synthetic mRNA into mouse muscle, successfully producing proteins in vivo—an early hint at mRNA's therapeutic potential. See: time.com+3penntoday.upenn.edu+3science.org+3en.wikipedia.org+4en.wikipedia.org+4en.wikipedia.org+4.

Despite the promise, these pioneering experiments raised fundamental obstacles: mRNA's inherent fragility, strong immunogenicity, and inefficient cellular delivery.

2. Cracking the Code: Reducing Immunogenicity via Nucleoside Modification

  • 1997–1998 – The Penn Collaboration Begins
    At the University of Pennsylvania, biochemist Katalin Karikó and immunologist Drew Weissman formed a partnership driven by a shared interest in harnessing mRNA. See: nature.com+15bu.edu+15teenvogue.com+15.

  • 2005 – Seminal Discovery

    They revealed that unmodified synthetic mRNA activates Toll‑like receptors in dendritic cells, triggering inflammation. Crucially, swapping out uridine with pseudouridine (or other modified nucleosides) dramatically suppressed this response, mitigating immunogenicity and enhancing protein translation. See: jbiomedsci.biomedcentral.com+15nobelprize.org+15jci.org+15.


These findings marked a watershed—chemical modification of mRNA transformed it into a viable therapeutic candidate, earning the duo the 2023 Nobel Prize in Physiology or Medicine. See: en.wikipedia.org+3time.com+3nobelprize.org+3

3. Packaging Success: Lipid Nanoparticles Enable Delivery

  • Development of mRNA-LNP Systems

    Research in the late 2000s and 2010s refined LNP formulations tailored to shield mRNA from degradation, enable cellular entry, and facilitate efficient endosomal escape. See: mdpi.compubs.rsc.org.

Notable innovations include ionizable lipids, helper lipids, cholesterol, and PEGylated lipids, collectively optimizing pharmacokinetics, stability, and safety. See: mdpi.com.

  • Clinical Translation

    This chemistry and engineering synergy culminated in the approval and deployment of the first lipid nanoparticle-based mRNA vaccines during the COVID-19 pandemic.

4. Pre-Pandemic Explorations

Even before 2020, mRNA therapeutics were under active development:

  • Cancer Vaccines: Preclinical and early clinical trials featured mRNA encoding tumor-specific antigens delivered via LNPs to prime anti‑tumor immunity.

  • Infectious Disease Vaccines: mRNA vaccines targeting rabies, Zika, influenza, and HIV entered early human trials, demonstrating both feasibility and promise. See: arxiv.org+3teenvogue.com+3wired.com+3.

  • Protein Replacement and Gene Editing: Applications using LNP-delivered mRNA for protein replacement therapies and CRISPR editing emerged in preclinical stages. See: mdpi.com+2pmc.ncbi.nlm.nih.gov+2pubs.rsc.org+2.

  • Pioneering Companies: Moderna (founded 2010) and BioNTech (2008) both built platforms centered on Karikó/Weissman technology and LNPs. BioNTech later partnered with Pfizer to develop its COVID-19 vaccine regimen.

5. The COVID‑19 Catalyst & Rapid Deployment

When SARS-CoV‑2 emerged in early 2020, the platform's modular nature and advanced formulations enabled unprecedented speed:

  • Clinical Trials: Moderna began human trials in March 2020. By December, both mRNA‑1273 (Moderna) and BNT162b2 (Pfizer‑BioNTech) secured Emergency Use Authorization based on ~95% efficacy. See: nature.com.

This success validated decades of incremental innovation: nucleoside-modified mRNA + optimized LNPs = real-world impact.

6. Recognition: The Nobel and Beyond

The scientific community honored Karikó and Weissman's pivotal contributions:

7. Beyond Vaccination: Broadening the mRNA Horizon

The mRNA platform's adaptability has ignited diverse research avenues:

  • Cancer Therapies: Personalized mRNA vaccines targeting neoantigens, mRNA‑encoded cytokines, and CAR-T therapies are progressing in clinical evaluation.

  • Gene Editing & Protein Replacement: mRNA-driven CRISPR approaches for in vivo editing, and LNP-encoded enzyme replacement therapies (e.g., for genetic disorders) are expanding mdpi.com+1jbiomedsci.biomedcentral.com+1.

  • Autoimmunity & Regenerative Medicine: Early-stage efforts are exploring mRNA-induced immune tolerance and tissue regeneration applications.


8. Continued Innovation & Challenges

Despite remarkable success, key areas require continued innovation:

  • Delivery Precision: Next-gen LNPs (e.g., organ-selective or SORT nanoparticles) aim to enable tissue-specific targeting beyond the liver en.wikipedia.org+1arxiv.org+1.

  • Stability & Design Optimization: Advanced methods like codon optimization and structure-prediction algorithms (e.g., LinearDesign) enhance mRNA stability and translational efficiency arxiv.org.

  • Manufacturing Scale & Supply: Scaling up mRNA and LNP production, maintaining cold chain logistics, and ensuring global access remain formidable obstacles wired.com+1mdpi.com+1.

  • Safety & Regulation: Comprehensive long-term safety monitoring—especially with novel ionizable lipids and repeated dosing—is critical pmc.ncbi.nlm.nih.gov.

  • Cost & Accessibility: Ensuring equitable pricing and widespread distribution, especially to low- and middle-income countries, remains essential.

9. Timeline of Key Milestones

Year Breakthrough

1961 Discovery of mRNA

1990 Synthetic mRNA expression in mice

1997–98 Karikó & Weissman collaboration begins

2005 Pseudouridine‑modified mRNA suppresses immune activation

2018 FDA approves LNP‑siRNA therapy Onpattro

2020 First mRNA COVID‑19 vaccine trials and rollout

2023 Nobel Prize for Karikó & Weissman

10. In Conclusion: A Platform Reborn

The mRNA story is a testament to scientific persistence, collaboration, and cumulative innovation. From a molecular curiosity to a global vaccine solution, the ascent of mRNA illustrates how challenges—fragility, immunogenicity, delivery—were methodically overcome with modified nucleosides and precision lipid carriers.

The result? A modular, adaptable therapeutic platform poised to revolutionize vaccines, cancer therapy, gene editing, and more. Let this narrative serve both as a chronicle of what has been achieved and a roadmap for what's next in the pharma world.

Your Organization and bench-to-bedside Drug Development with Metis Consulting Services

The groundbreaking advancements in mRNA technology demonstrate the power of specialized expertise and meticulous scientific guidance in navigating complex drug development landscapes. Just as decades of dedicated research led to the mRNA revolution, your next therapeutic breakthrough requires seasoned insight and strategic direction.

Don't leave your innovative drug development projects to chance. Let Metis Consulting Services help to leverage unparalleled expertise in navigating the intricate pathways of pharmaceutical research and development. We provide comprehensive guidance, from early-stage discovery to clinical translation, ensuring your projects are optimized for success.

Contact Metis Consulting Services today to unlock the full potential of your drug development pipeline and turn scientific aspirations into real-world impact.

Be sure to check out our podcast, Queens of Quality for more informative and interesting conversations about this and more bio/pharma hot topics.

Read More